Vulvar Pain Management

Diagnostic Approach

Vulvovaginal candidiasis (VVC) presents with vulvar pruritus, burning, erythema, and often white discharge with normal vaginal pH ≤4.5, according to the Centers for Disease Control and Prevention (CDC) 1, 2
Vulvovaginal atrophy causes dryness, dyspareunia, and tissue fragility, typically in postmenopausal women or those on endocrine therapy, as reported by the American Society of Clinical Oncology 3, 4

The CDC recommends topical azole creams as the first-line treatment for VVC, achieving 80-90% symptom relief, with options including clotrimazole 1% cream, miconazole 2% cream, terconazole 0.4% cream, and butoconazole 2% cream 1, 2, 5
Multi-day regimens (7-day) are preferred for severe or complicated VVC over single-dose treatments, as suggested by the CDC 1, 5
Only treat symptomatic patients, as 10-20% of women harbor Candida asymptomatically, according to the CDC 1, 2
During pregnancy, use only topical azoles (not oral agents) for 7 days, as recommended by the CDC 5

The American Society of Clinical Oncology suggests a stepwise approach starting with non-hormonal options, including vaginal lubricants for sexual activity plus daily vaginal moisturizers 3, 4
Low-dose vaginal estrogen cream (Estrace 1g containing 0.625mg estradiol) can be used for vulvovaginal atrophy, applied intravaginally daily for 2 weeks, then twice weekly for maintenance, with symptom relief in 80-90% of patients within 4-8 weeks, as reported by the American College of Obstetricians and Gynecologists 6
Vaginal DHEA (prasterone) can be used for women on aromatase inhibitors who haven't responded to other treatments, and ospemifene (oral SERM) can be used for postmenopausal women without history of breast cancer, as suggested by the American Society of Clinical Oncology 3, 4, 6

The American Society of Clinical Oncology recommends topical lidocaine for persistent introital pain and dyspareunia, which can be offered for symptom relief 3, 4

The CDC advises against using topical antifungals for non-candidal vulvar pain, as this delays appropriate diagnosis and treatment 1, 2
Women with recurrent symptoms (≥3 episodes/year of VVC or symptoms persisting >2 months) require medical evaluation, not continued self-treatment, as recommended by the CDC 1, 5, 7
Pelvic floor physiotherapy should be offered for any persistent vulvar pain or pelvic floor dysfunction, as suggested by the American Society of Clinical Oncology 3, 4